Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …

Background French national health care insurance system database has suggested 1–3
years use of glucagon like peptide-1 receptor agonists (GLP1RA)(exenatide, liraglutide and …

Abstract Purpose of Review This review aims to detail the current global research state of
metabolically healthy obesogenesis with regard to metabolic factors, disease prevalence …

Objective Weight loss interventions to treat obesity include sleeve gastrectomy (SG), lifestyle
intervention (LI), endoscopic sleeve gastroplasty (ESG) and semaglutide. We aimed to …

Purpose Semaglutide has demonstrated safe and effective weight loss for overweight and
obesity, including participants with concomitant type 2 diabetes mellitus (T2DM), in …

Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …

Summary Type 2 diabetes (T2D), obesity, and nonalcoholic fatty liver disease/nonalacoholic
steatohepatitis (NAFLD/NASH) share mutual causalities. Medications that may offer clinical …

Obesity is a heterogeneous condition which results from complex interactions among
sex/gender, sociocultural, environmental, and biological factors. Obesity is more prevalent in …

Obesity is highly prevalent in hepatology clinics and has significant impact in chronic liver
disease and patient management. Hepatologists and gastroenterologist need to be actively …

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable
attention as a therapeutic agent for type 2 diabetes mellitus and obesity. Despite its clinical …